# Weight change and the risk of chronic pain following hip and knee arthroplasties: A nationwide registry-based cohort survey study.

#### Authors/Collaborators:

Saber M. Saber<sup>1,2,3</sup>, MD, PhD Fellow; Jens Laigaard<sup>1,3</sup>, MD, PhD Fellow; Martin Lindberg-Larsen, MD, PhD, Associate professor<sup>4</sup>; Søren Overgaard, MD, DMSc, Professor<sup>1,3</sup>

#### Affiliations:

1. Department of Orthopaedic Surgery and Traumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; 2. The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; 3. University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences; 4. Department of Orthopaedic Surgery and Traumatology, Odense Hospital, Odense, Denmark.

#### INTRODUCTION

The treatment of hip and knee osteoarthritis not responding to non-surgical treatments may be surgical joint arthroplasty.<sup>1</sup> Though arthroplasty is considered an effective and safe treatment, unfavourable outcomes have been reported,<sup>2</sup> including persistent postoperative pain (PPP). The association between body weight and outcomes following total hip arthroplasty (THA) and knee arthroplasty is well documented: overweight carries higher risk of bad functional and surgical outcomes.<sup>3-9</sup> Also, Preoperative weight reduction reduces general health related complications following knee arthroplasty.<sup>10</sup> However, only few studies have investigated weight change following THA and knee arthroplasty.<sup>11-16</sup> Of these, some have indicated that weight change influences postsurgical outcomes.

Identification of factors that are linked to the incidence of PPP could help us to prevent this problematic outcome. The objective of this study is to investigate whether weight change is associated with the incidence of PPP following THA and knee arthroplasty across non-obese and obese and patients.

#### METHODS

#### Study design

The study is a nationwide, register-based cohort survey study. We will report the results following the CROSS checklist for standardized reporting of survey studies.<sup>17</sup> We will investigate the change of BMI 11-15 months after THA and knee arthroplasty and incidence of PPP by combining data from national registries and surveys.

#### Questionnaire

A 22-question questionnaire will be sent to the eligible candidates (see NCTo5900791 and NCTo5845177). The questionnaire is developed by combining domains from previously validated Patient Reported Outcome Measures (PROMs). Five questions are taken from the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain domain; seven questions from the Douleur Neuropathique 4 interview (DN4i); a numerical rating scale (NRS) question for pain in the operated joint in the last week; satisfaction; a single question for each of the following: willingness to repeat the surgery; pain frequency; pain interference with daily activities; other chronic pain conditions; patient-reported use of analgesics; weight; height and the permission to contact respondents again later. Patient reported weight and height has been recently found valid in a Danish e-survey setting.<sup>18</sup> A detailed description of the questionnaires and the current validation status of the domains can be found in 2 different papers.<sup>19,20</sup> The Danish and an English version of the questionnaire will be available in the final publication.

## Sample characteristics

Patients with THA and knee arthroplasty who received their arthroplasty 11-15 months prior to the intended date of survey administration will be identified based on the NOMESCO (Nordic Medico-Statistical Committee) Classification of Surgical Procedures from the the Danish National Patient Register by using SKS-code. The codes for THA patients will be SKS-code DM16 [hip osteoarthritis] + KNFB20 or KNFB30 or KNFB40[Primary Total Hip Arthroplasty]. For total knee arthroplasty (TKA), SKS-code DM17 [knee osteoarthritis] + KNGB20, KNGB30 or KNGB40 [primary total knee arthroplasty]). For medial unicompartmental knee arthroplasty (UKA), SKS-code DM17 [knee osteoarthritis] + KNGB01 or KNGB11 [primary medial unicompartmental knee arthroplasty]. The baseline characteristics of the sample including their BMI will be gathered from the Danish Hip Arthroplasty Register (DHR) and the Danish Knee Arthroplasty Register (DKR).

# Survey administration

The data of this study is pooled from 2 surveys sent to THA and knee arthroplasty patients.<sup>19,20</sup> Both surveys are distributed via 'Digital Post' which is linked to the unique Civil Registration number (CPR) using Research Electronic Data Capture (REDCap) software (<u>www.r-project.org</u>). A reminder will be sent 14 days after distribution for non-responders. A month after distribution date, a text-message will be sent to non-responder's telephone number if it is registered in the electronic patient file.

# **Statistical analysis**

We expect to find a sample of around 6400 patients divided between hip and knee arthroplasty. Estimated response rates of 70% will leave us with 2240 patients to be analysed in each joint arthroplasty group. With an expected 15% of the sample to be weight gainers, we will be able to detect a minimum of 16.6% difference in the incidence of the outcome between gainers and non-gainers with a significance level of 0.05 with a power of 0.80.

We will report results for THA, TKA and medial UKA separately as we believe these are different patient groups. We will categorize patients into weight gainers ( $\geq$ 5% weight gain after arthroplasty), weight losers ( $\geq$ 5% weight loss) and those who maintain their weight. Descriptive statistics of the baseline characteristics of the three categories with the following variables will be presented in table 1: age, sex, BMI and surgical details (type of anaesthesia, operation length, use of local infiltration analgesia (LIA), use of cement, and surgical complications).

The primary outcome is the occurrence of PPP and will be defined as NRS pain score higher than 3 as proposed by Moore et. al.<sup>21</sup> Secondary outcomes include satisfaction defined as being very satisfied or

satisfied; willingness to repeat the surgery defined as answering "yes" in willingness question; frequent pain defined as experiencing pain constantly, daily or few times a week; use of analgesic; interference with daily activities, defined as answering "some", "much" and "very much"; WOMAC pain score will be reported as the mean (standard deviation [SD]). Following outcome dichotomization (except for WOMAC pain), we will employ a multivariate logistic regression model to estimate the Odds Ratio (OR) and the corresponding 95% Confidence Interval (CI) amongst gainers and losers in relation to those who maintained their weight. For WOMAC pain, we will report the mean difference (MD) and the corresponding 95% CI. We will stratify for baseline obesity status (non-obese: BMI < 30 kg/m<sup>2</sup>, Obese: BMI ≥ 30 kg/m<sup>2</sup>). We will run a non-adjusted analysis first, then we will adjust for age, sex and the use of cement. We will do a sensitivity analysis to see whether the effect size is different between non-morbidly obese (BMI 30-39 kg/m<sup>2</sup>) and morbidly obese (BMI ≥ 40 kg/m<sup>2</sup>), we will run another sensitivity analysis adjusting for patients having other chronic pain condition. Data is handled in the most recent version of R (www.r-project.org).

Table 1 (Demo	graphics	)								
		THA			TKA		Medial UKA			
Demographi	Weigh	Weigh	Weight	Weigh	Weigh	Weight	Weigh	Weigh	Weight	
CS	t	t	unchange	t	t	unchange	t	t	unchange	
	gainer	losers	d	gainer	losers	d	gainer	losers	d	
	s			s			S			
Total N										
Age (mean)										
Female N										
(%)										
BMI (mean)										
General										
Anaesthesia										
N (%)										
Spinal										
Anaesthesia										
N (%)										
Operation										
time (mean)										

Use of					
Cement N					
(%)					
Local					
Infiltration of					
analgesia N					
(%)					
Surgical					
complication					
N (%)					

Table 2 (Risk	of	levelop	ing PPP	')										
	Weight unchanged			Weight gainers					Weight losers					
	(Reference group)													
	Ν	PPP:	P: OR P		Ν	PPP:	OR	Adjusted	Р	Ν	PPP:	OR	Adjusted	Р
		Ν	(95%	value		Ν	(95%	OR (95%	value		Ν	(95%	OR (95%	value
		(%)	CI)			(%)	CI)	CI)			(%)	CI)	CI)	
ТНА														
Non-			1											
Obese														
Obese			1											
ТКА														
Non-			1											
Obese														
Obese			1											
Medial														
UKA														
Non-			1											
Obese														
Obese			1											

## HEALTH RESEARCH ETHICS AND GENERAL CONSIDERATIONS

## Funding

Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL), which had no role in study design or writing of this protocol.

# Patient and Public Involvement (PPI)

This project follows the EULAR recommendations for the inclusion of patient representatives in the contemporary scientific process.<sup>22</sup> A panel of patients helped in developing the questionnaire.

# **Conflict of interest**

All will be disclosed.

# Disclaimers

The views expressed in the submitted protocol are the authors' own and not an official position of the institution or funder.

# Ethics

The local institutional review board approved the study, and the Danish Health Data Authority will provide contact information for potential respondents. Telephone numbers for non-respondents are found by searching the CPR number in the electronic patient files, but without accessing the patients' health data. According to Danish legislation, approval from the national ethics committee is neither required nor possible to obtain for survey studies.

Because we will link survey responses with perioperative data from the Danish Knee Arthroplasty Register, responses are not anonymous. However, only the authors will have access to confidential information and data will be anonymised as soon as possible. Until then, the data are stored pseudonymised at a logged and encrypted drive.

# REFERENCES

- 1. Gademan, M.G., Hofstede, S.N., Vliet Vlieland, T.P., Nelissen, R.G. & Marang-van de Mheen, P.J. Indication criteria for total hip or knee arthroplasty in osteoarthritis: a state-of-the-science overview. *BMC Musculoskelet Disord* **17**, 463 (2016).
- Heo, S.M., Harris, I., Naylor, J. & Lewin, A.M. Complications to 6 months following total hip or knee arthroplasty: observations from an Australian clinical outcomes registry. *BMC Musculoskelet Disord* 21, 602 (2020).
- 3. Hungerford, M.W., Schuh, R., O'Reilly, M.P. & Jones, L.C. Outcome of minimally invasive hip replacement in obese, overweight, and nonobese patients. *J Surg Orthop Adv* **23**, 68-74 (2014).
- 4. Busato, A., Röder, C., Herren, S. & Eggli, S. Influence of high BMI on functional outcome after total hip arthroplasty. *Obes Surg* **18**, 595-600 (2008).
- Liljensøe, A., Lauersen, J.O., Søballe, K. & Mechlenburg, I. Overweight preoperatively impairs clinical outcome after knee arthroplasty: a cohort study of 197 patients 3–5 years after surgery. *Acta Orthop* 84, 392-397 (2013).
- 6. Polat, A.E., Polat, B., Gürpınar, T., Çarkçı, E. & Güler, O. The effect of morbid obesity (BMI ≥ 35 kg/m(2)) on functional outcome and complication rate following unicompartmental knee arthroplasty: a case-control study. *J Orthop Surg Res* **14**, 266 (2019).
- 7. Wilson, C.J., *et al.* Surgical site infection in overweight and obese Total Knee Arthroplasty patients. *J Orthop* **15**, 328-332 (2018).
- 8. Lübbeke, A., *et al.* Body mass and weight thresholds for increased prosthetic joint infection rates after primary total joint arthroplasty. *Acta Orthop* **87**, 132-138 (2016).
- 9. Jung, P., *et al.* BMI is a key risk factor for early periprosthetic joint infection following total hip and knee arthroplasty. *N Z Med J* **130**, 24-34 (2017).
- 10. Liljensoe, A., Laursen, J.O., Bliddal, H., Soballe, K. & Mechlenburg, I. Weight Loss Intervention Before Total Knee Replacement: A 12-Month Randomized Controlled Trial. *Scand J Surg* **110**, 3-12 (2021).
- 11. Wu, M., *et al.* Patterns and Predictors of Weight Change Before and After Total Hip Arthroplasty in Class 2 and 3 Obese Patients. *J Arthroplasty* **37**, 880-887 (2022).
- 12. Naylor, J.M., *et al.* Patient factors associated with weight gain and weight loss after knee or hip arthroplasty. *Obes Res Clin Pract* **13**, 371-377 (2019).
- 13. Stock, L.A., Brennan, J.C., Turcotte, J.J. & King, P.J. Effect of Weight Change on Patient-Reported Outcomes Following Total Joint Arthroplasty. *J Arthroplasty* **37**, 1991-1997.e1991 (2022).
- 14. Lim, C.T., *et al.* Weight Gain After Primary Total Knee Arthroplasty Is Associated With Accelerated Time to Revision for Aseptic Loosening. *J Arthroplasty* **32**, 2167-2170 (2017).
- 15. Riddle, D.L., Singh, J.A., Harmsen, W.S., Schleck, C.D. & Lewallen, D.G. Clinically important body weight gain following total hip arthroplasty: a cohort study with 5-year follow-up. *Osteoarthritis Cartilage* **21**, 35-43 (2013).
- 16. Inacio, M.C., *et al.* Weight patterns before and after total joint arthroplasty and characteristics associated with weight change. *Perm J* **18**, 25-31 (2014).
- 17. Sharma, A., et al. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med **36**, 3179-3187 (2021).
- 18. Christensen, A.I., *et al.* The Danish National Health Survey: Study design, response rate and respondent characteristics in 2010, 2013 and 2017. *Scand J Public Health* **50**, 180-188 (2022).
- 19. Laigaard, J. Persistent Pain After Hip Replacement. (<u>https://clinicaltrials.gov/show/NCT05845177</u>, 2023).
- 20. Laigaard, J. Persistent Pain After Knee Replacement. (<u>https://clinicaltrials.gov/study/NCT05900791</u>, 2023).
- 21. Moore, R.A., Straube, S. & Aldington, D. Pain measures and cut-offs 'no worse than mild pain' as a simple, universal outcome. *Anaesthesia* **68**, 400-412 (2013).

22. De Wit, M.P.T., *et al.* European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. *Annals of the Rheumatic Diseases* **70**, 722-726 (2011).